Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
The human monoclonal antibody tralokinumab significantly reduced skin colonization by Staphylococcus aureus (S. aureus) in adults with moderate-to-severe atopic dermatitis (AD), according to a study presented at ISDS 2018.
Interleukin 17A (IL-17A) antagonist ixekizumab demonstrates superior efficacy and similar safety outcomes compared with IL-12/23 inhibitor ustekinumab through 52 weeks of treatment, according to the results of a phase III trial.
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
A 10-year retrospective study at Singapore General Hospital (SGH) has shown that majority of patients with tinea unguium, a common nail infection, are aged ≥60 years. In this cohort, patients of Indian and other ethnicities are over-represented for tinea unguium compared to Chinese and Malay patients.